|
1
|
Abedizadeh R, Majidi F, Khorasani HR,
Abedi H and Sabour D: Colorectal cancer: A comprehensive review of
carcinogenesis, diagnosis, and novel strategies for classified
treatments. Cancer Metastasis Rev. 43:729–753. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tao XY, Li QQ and Zeng Y: Clinical
application of liquid biopsy in colorectal cancer: Detection,
prediction, and treatment monitoring. Mol Cancer. 23:1452024.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mousavi SE, Ilaghi M, Hamidi Rad R and
Nejadghaderi SA: Epidemiology and socioeconomic correlates of
colorectal cancer in Asia in 2020 and its projection to 2040. Sci
Rep. 15:266392025. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang Y, Wang Y, Zhang B, Li P and Zhao Y:
Methods and biomarkers for early detection, prediction, and
diagnosis of colorectal cancer. Biomed Pharmacother.
163:1147862023. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mo S, Tang P, Luo W, Zhang L, Li Y, Hu X,
Ma X, Chen Y, Bao Y, He X, et al: Patient-derived organoids from
colorectal cancer with paired liver metastasis reveal tumor
heterogeneity and predict response to chemotherapy. Adv Sci
(Weinh). 9:e22040972022. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang W and Wang S: Relationships between
nutritional status and serum adipokine levels with chemotherapy
efficacy in late-stage colorectal cancer patients. Int J Colorectal
Dis. 40:252025. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Prasetyanti PR and Medema JP: Intra-tumor
heterogeneity from a cancer stem cell perspective. Mol Cancer.
16:412017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yu X, Liu R, Gao W, Wang X and Zhang Y:
Single-cell omics traces the heterogeneity of prostate cancer cells
and the tumor microenvironment. Cell Mol Biol Lett. 28:382023.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Guo L, Wang Y, Yang W, Wang C, Guo T, Yang
J, Shao Z, Cai G, Cai S, Zhang L, et al: Molecular profiling
provides clinical insights into targeted and immunotherapies as
well as colorectal cancer prognosis. Gastroenterology.
165:414–428.e7. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Singh H, Sahgal P, Kapner K, Corsello SM,
Gupta H, Gujrathi R, Li YY, Cherniack AD, El Alam R, Kerfoot J, et
al: RAS/RAF Comutation and ERBB2 copy number modulates HER2
heterogeneity and responsiveness to HER2-directed therapy in
colorectal cancer. Clin Cancer Res. 30:1669–1684. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jalali P, Aliyari S, Etesami M, Saeedi
Niasar M, Taher S, Kavousi K, Nazemalhosseini Mojarad E and Salehi
Z: GUCA2A dysregulation as a promising biomarker for accurate
diagnosis and prognosis of colorectal cancer. Clin Exp Med.
24:2512024. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lu S, Sun X, Tang H, Yu J, Wang B, Xiao R,
Qu J, Sun F, Deng Z, Li C, et al: Colorectal cancer with low
SLC35A3 is associated with immune infiltrates and poor prognosis.
Sci Rep. 14:3292024. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Parisi E, Hidalgo I, Montal R, Pallise O,
Tarragona J, Sorolla A, Novell A, Campbell K, Sorolla MA, Casali A
and Salud A: PLA2G12A as a novel biomarker for colorectal cancer
with prognostic relevance. Int J Mol Sci. 24:108892023. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jackson HW, Defamie V, Waterhouse P and
Khokha R: TIMPs: Versatile extracellular regulators in cancer. Nat
Rev Cancer. 17:38–53. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Caterina NC, Windsor LJ, Bodden MK,
Yermovsky AE, Taylor KB, Birkedal-Hansen H and Engler JA:
Glycosylation and NH2-terminal domain mutants of the tissue
inhibitor of metalloproteinases-1 (TIMP-1). Biochim Biophys Acta.
1388:21–34. 1388. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Justo BL and Jasiulionis MG:
Characteristics of TIMP1, CD63, and β1-Integrin and the functional
impact of their interaction in cancer. Int J Mol Sci. 22:93192021.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Eckfeld C, Haussler D, Schoeps B, Hermann
CD and Kruger A: Functional disparities within the TIMP family in
cancer: Hints from molecular divergence. Cancer Metastasis Rev.
38:469–481. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tian Z, Ou G, Su M, Li R, Pan L, Lin X,
Zou J, Chen S, Li Y, Huang K and Chen Y: TIMP1 derived from
pancreatic cancer cells stimulates Schwann cells and promotes the
occurrence of perineural invasion. Cancer Let. 546:2158632022.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Guccini I, Revandkar A, D'Ambrosio M,
Colucci M, Pasquini E, Mosole S, Troiani M, Brina D,
Sheibani-Tezerji R, Elia AR, et al: Senescence reprogramming by
TIMP1 deficiency promotes prostate cancer metastasis. Cancer Cell.
39:68–82.e9. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chandrashekar DS, Karthikeyan SK, Korla
PK, Patel H, Shovon AR, Athar M, Netto GJ, Qin ZS, Kumar S, Manne
U, et al: UALCAN: An update to the integrated cancer data analysis
platform. Neoplasia. 25:18–27. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chandrashekar DS, Bashel B, Balasubramanya
SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi B and Varambally
S: UALCAN: A portal for facilitating tumor subgroup gene expression
and survival analyses. Neoplasia. 19:649–658. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tang Z, Kang B, Li C, Chen T and Zhang Z:
GEPIA2: An enhanced web server for large-scale expression profiling
and interactive analysis. Nucleic Acids Res. 47:W556–W560. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sveen A, Agesen TH, Nesbakken A, Rognum
TO, Lothe RA and Skotheim RI: Transcriptome instability in
colorectal cancer identified by exon microarray analyses:
Associations with splicing factor expression levels and patient
survival. Genome Med. 3:322011. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang Z, Wang Y, Peng M and Yi L: UBASH3B
is a novel prognostic biomarker and correlated with immune
infiltrates in prostate cancer. Front Oncol. 9:15172019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Thorsson V, Gibbs DL, Brown SD, Wolf D,
Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy
JA, et al: The immune landscape of cancer. Immunity.
48:812–830.e14. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bonneville R, Krook MA, Kautto EA, Miya J,
Wing MR, Chen HZ, Reeser JW, Yu L and Roychowdhury S: Landscape of
microsatellite instability across 39 cancer types. JCO Precis
Oncol. 2017.PO.17.00073. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wei J, Huang K, Chen Z, Hu M, Bai Y, Lin S
and Du H: Characterization of glycolysis-associated molecules in
the tumor microenvironment revealed by pan-cancer tissues and lung
cancer single cell data. Cancers (Basel). 12:17882020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hanzelmann S, Castelo R and Guinney J:
GSVA: Gene set variation analysis for microarray and RNA-seq data.
BMC Bioinformatics. 14:72013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Xiao Z, Dai Z and Locasale JW: Metabolic
landscape of the tumor microenvironment at single cell resolution.
Nat Commun. 10:37632019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sun L, Chen Y, Xia L, Wang J, Zhu J, Li J,
Wang K, Shen K, Zhang D, Zhang G, et al: TRIM69 suppressed the
anoikis resistance and metastasis of gastric cancer through
ubiquitin-proteasome-mediated degradation of PRKCD. Oncogene.
42:3619–3632. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kendre G, Murugesan K, Brummer T, Segatto
O, Saborowski A and Vogel A: Charting co-mutation patterns
associated with actionable drivers in intrahepatic
cholangiocarcinoma. J Hepatol. 78:614–626. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Di Mauro A, Santorsola M, Savarese G,
Sirica R, Ianniello M, Cossu AM, Ceccarelli A, Sabbatino F,
Bocchetti M, Carratu AC, et al: High tumor mutational burden
assessed through next-generation sequencing predicts favorable
survival in microsatellite stable metastatic colon cancer patients.
J Transl Med. 22:11072024. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shi S, Wang Y, Wu J, Zha B, Li P, Liu Y,
Yang Y, Kong J, Gao S, Cui H, et al: Predictive value of PD-L1 and
TMB for short-term efficacy prognosis in non-small cell lung cancer
and construction of prediction models. Front Oncol. 14:13422622024.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hou W, Yi C and Zhu H: Predictive
biomarkers of colon cancer immunotherapy: Present and future. Front
Immunol. 13:10323142022. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sasidharan Nair V, Saleh R, Taha RZ, Toor
SM, Murshed K, Ahmed AA, Kurer MA, Abu Nada M, Al Ejeh F and Elkord
E: Differential gene expression of tumor-infiltrating
CD4+ T cells in advanced versus early stage colorectal
cancer and identification of a gene signature of poor prognosis.
Oncoimmunology. 9:18251782020. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Garborg K: Colorectal cancer screening.
Surg Clin North Am. 95:979–989. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Tonini V and Zanni M: Why is early
detection of colon cancer still not possible in 2023? World J
Gastroenterol. 30:211–224. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zheng M, Wang P, Wang Y, Jia Z, Gao J, Tan
X, Chen H and Zu G: Clinicopathological and prognostic significance
of TIMP1 expression in gastric cancer: A systematic review and
meta-analysis. Expert Rev Anticancer Ther. 24:1169–1176. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Dantas E, Murthy A, Ahmed T, Ahmed M,
Ramsamooj S, Hurd MA, Lam T, Malbari M, Agrusa C, Elemento O, et
al: TIMP1 is an early biomarker for detection and prognosis of lung
cancer. Clin Transl Med. 13:e13912023. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Macedo FC, Cunha N, Pereira TC, Soares RF,
Monteiro AR, Bonito N, Valido F and Sousa G: A prospective cohort
study of TIMP1 as prognostic biomarker in gastric and colon cancer.
Chin Clin Oncol. 11:432022. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zheng J, Peng L, Zhang S, Liao H, Hao J,
Wu S and Shen H: Preoperative systemic immune-inflammation index as
a prognostic indicator for patients with urothelial carcinoma.
Front Immunol. 14:12750332023. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Xiong S, Dong L and Cheng L: Neutrophils
in cancer carcinogenesis and metastasis. J Hematol Oncol.
14:1732021. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Liu R, Lu J, Liu J, Liao Y, Guo Y, Shi P,
Wang Z, Wang H and Lai J: Macrophages in prostate cancer: Dual
roles in tumor progression and immune evasion. J Transl Med.
23:6152025. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lin X, Zhao R, Bin Y, Huo R, Xue G and Wu
J: TIMP1 promotes thyroid cancer cell progression through
macrophage phenotypic polarization via the PI3K/AKT signaling
pathway. Genomics. 116:1109142024. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Liu L, Yang S, Lin K, Yu X, Meng J, Ma C,
Wu Z, Hao Y, Chen N, Ge Q, et al: Sp1 induced gene TIMP1 is related
to immune cell infiltration in glioblastoma. Sci Rep. 12:111812022.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Xu J, Wei C, Wang C, Li F, Wang Z, Xiong
J, Zhou Y, Li S, Liu X, Yang G, et al: TIMP1/CHI3L1 facilitates
glioma progression and immunosuppression via NF-kappaB activation.
Biochim Biophys Acta Mol Basis Dis. 1870:1670412024. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wang CA, Hou YC, Hong YK, Tai YJ, Shen C,
Hou PC, Fu JL, Wu CL, Cheng SM, Hwang DY, et al: Intercellular
TIMP-1-CD63 signaling directs the evolution of immune escape and
metastasis in KRAS-mutated pancreatic cancer cells. Mol Cancer.
24:252025. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Butterfield LH and Najjar YG:
Immunotherapy combination approaches: Mechanisms, biomarkers and
clinical observations. Nat Rev Immunol. 24:399–416. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Bai R, Lv Z, Xu D and Cui J: Predictive
biomarkers for cancer immunotherapy with immune checkpoint
inhibitors. Biomark Res. 8:342020. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Song G, Xu S, Zhang H, Wang Y, Xiao C,
Jiang T, Wu L, Zhang T, Sun X, Zhong L, et al: TIMP1 is a
prognostic marker for the progression and metastasis of colon
cancer through FAK-PI3K/AKT and MAPK pathway. J Exp Clin Cancer
Res. 35:1482016. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Ma B, Ueda H, Okamoto K, Bando M, Fujimoto
S, Okada Y, Kawaguchi T, Wada H, Miyamoto H, Shimada M, et al:
TIMP1 promotes cell proliferation and invasion capability of
right-sided colon cancers via the FAK/Akt signaling pathway. Cancer
Sci. 113:4244–4257. 2022. View Article : Google Scholar : PubMed/NCBI
|
